Desogestrel Availability in the USA
Desogestrel is available in the United States, but only in combination oral contraceptive formulations with ethinyl estradiol, not as a standalone progestin-only pill.
Available Formulations in the USA
Based on FDA drug labeling, desogestrel is marketed in the United States as:
- Combined oral contraceptives: Desogestrel 0.15 mg combined with ethinyl estradiol (0.02 mg or 0.01 mg) 1
- These are available as monophasic formulations containing 21 active tablets plus placebo tablets
Important Distinction: Progestin-Only Pills
The desogestrel-only contraceptive pill (Cerazette®, 0.075 mg) that is widely available in Europe and other countries is NOT available in the United States 2.
In France and other European countries, two types of progestin-only pills are available:
- Levonorgestrel 0.03 mg (Microval®)
- Desogestrel 0.075 mg (Cerazette®) 2
However, U.S. guidelines on contraception 3, 4 do not list desogestrel-only pills among available progestin-only contraceptive options in the United States.
Alternative Progestin-Only Options in the USA
If a progestin-only contraceptive is needed, the following are available in the United States 4:
- Levonorgestrel progestin-only pills (0.75 mg split dose or 1.5 mg single dose for emergency contraception)
- Etonogestrel implant (Nexplanon®) - notably, etonogestrel is the active metabolite of desogestrel
- Levonorgestrel IUD (Mirena®)
- Depot medroxyprogesterone acetate (DMPA) injections
Clinical Context
Desogestrel is a third-generation progestin that has been extensively studied and used in Europe for decades 5, 6. When taken orally, desogestrel is rapidly metabolized to etonogestrel, which is the biologically active compound 1, 7. This same active metabolite (etonogestrel) is available in the U.S. via the contraceptive implant and vaginal ring (NuvaRing®).
The combined desogestrel/ethinyl estradiol formulations available in the U.S. have demonstrated excellent contraceptive efficacy with Pearl indices as low as 0.04 in European studies 6, though they carry the typical risks associated with combined hormonal contraceptives, including increased venous thromboembolism risk compared to second-generation progestins 2, 8.